Dr Ifedayo Adetifa
| Call | Career Development Fellowship (CDF) |
| Programme | EDCTP1 |
| Start Date | 2007-03-15 |
| End Date | 2010-07-01 |
| Project Code | TA.2005.40203.001 |
| Status | Completed |
Title
A double blind, placebo controlled randomized trial of vitamin A supplementation for modulation of Mycobacterium tuberculosis immune responses in children aged 5-14 years with latent Tuberculosis.
Objectives
To provide additional evidence for the performance of novel diagnostics for latent tuberculosis and TB case detection in adults and children especially those with paucibacillary disease in a TB endemic country; and to identify differences in immune responses may improve our understanding of what constitutes protection against progression to TB in those latently infected
Host Organisation
| Institution | Country |
|---|---|
| Medical Research Council | Gambia |
Participants
| Name | Institution | Country |
|---|---|---|
| Richard Adegbola | MRC Laboratories | Gambia |
| Martin Antonio | MRC Laboratories | Gambia |
| Philip Hill | MRC Laboratories | Gambia |
Study Design
Immunological studies in TB immunity
Sites
| N/A |
Phd Study
| Title | University | Start Date | End Date |
|---|---|---|---|
| Interferon Gamma Releaase Assays for Tuberculosis and their potential as efficacy markers for intervention trials | University of Amsteram | 2007-10-01 | 2012-10-12 |
Results & Outcomes
In a cross sectional study, the ELISPOT test was more sensitive than the QFT-GIT for diagnosing TB disease, but both tests performed similarly in the diagnosis of LTBI in TB contacts. In an extension of this study to two newly licensed commercial IGRAs, it was found that both IGRAs and the TST responded in a similar manner to a gradient of exposure to TB. In addition, each IGRA in combination with TST increased sensitivity for diagnosis of LTBI but was also associated with a loss of specificity. Also tested as Hain Sciences Line probe assay, MTBDRplus® in a 2 step-procedure. On 93 smear negative culture positive samples, the LPA had a sensitivity of 45.2% (42 of 93) and over half of the results were blank. There was no relationship between the results from post decontamination ZN concentration staining and failed LPA results. In assessing gene expression for cytokines protective against TB disease progression IFN-γ was significantly lower in progressors compared to both non-progressors and TB cases (p=0.0328 and p=0.0062 respectively). For other cytokines-IL-10 and IL-12 similar levels were seen between the groups. IL-18 was significantly higher in progressors compared to non-progressors and confirmed TB cases (p<0.001 for both).
Publications
| Adetifa IM et al. Mycobacterium tuberculosis Infection in close childhood contacts of adults with Pulmonary Tuberculosis is increased by Second-hand exposure to Tobacco. Am J Trop Med Hyg. 2017 Aug;97(2):429-432 |
| Hill PC et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 2007;4(6):e192 |
| Adetifa IM et al. Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis J. 2010;29(5):439-43 |
| Adetifa IM et al. A Tuberculin Skin Test Survey and the Annual Risk of Mycobacterium tuberculosis Infection in Gambian School Children. PLoS One (2015) 10(10):e0139354 |
| Buchwald, U.K et al. Broad Adaptive Immune Responses to M. tuberculosis Antigens Precede TST Conversion in Tuberculosis Exposed Household Contacts in a TB-Endemic Setting. PLoS One (2014) 9(12):e116268 |
| Morter R et al. Examining human paragonimiasis as a differential diagnosis to tuberculosis in The Gambia. BMC Res Notes (2018) 11:31 |
| Hill PC. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics. 2006;117(5):1542-8 |
Current Organisation
Department of Infectious Diseases Epidemiology London School of Hygiene and Tropical Medicine, London, United Kingdom
Current Job Title
Associate Professor/ Clinical Epidemiologist
Awards
| 2018 | MRC/DFID Africa Research Leader |
| 2013 | Medical Research Council, UK Chief Executive Officer’s Commendation for Rising Star |
| 2006 | Heinz Visiting Fellowship, Royal College of Paediatrics and Child Health, London, UK |
Students Supervised
| Type | Name | Title | University | Start Date | End Date |
|---|---|---|---|---|---|
| PhD | Aishatu Adamu | Predicting the impact of pneumococcal conjugate vaccines on invasive disease in Nigeria using changes in carriage | London School of Hygiene & Tropical Medicine | ||
| MPhil | Catherine bi Okoi | Non-tuberculous Mycobacteria in The Gambia: Prevalent Species, Carriage and Disease | Open University |
Memberships
| Role | Committee/board | Start Date | End Date |
|---|---|---|---|
| Member | Technical Advisory Group for Gates’ funded project, Assessing the feasibility of using serological data to monitor and guide immunization programs in low income countries at IVAC | 2016 | |
| Member | WHO Africa Regional Immunisation Technical Advisory Group | 2018 | |
| Member | World Health Organisation’s African Panel of Experts to assess the risk of autoimmune diseases among RTS,S malaria vaccine recipients | 2015 | 2015 |
Areas Of Specialisation
Tuberculosis (TB) Lower Respiratory Tract Infections (LRTIs)
Grants
Grant Code:
N/A
Source of funding:
Global Alliance for Vaccines and Immunisations
Amount:
2650000
Role:
Principal Investigator
Start Date:
2017-10-01
End Date:
2017-10-01
Grant Code:
Source of funding:
NIHR-MPRU at UCL
Amount:
128871
Role:
Principal Investigator
Start Date:
2018-01-01
End Date:
2020-01-01
Grant Code:
N/A
Source of funding:
MRC
Amount:
4100000
Role:
Principal Investigator
Start Date:
2010-07-01
End Date:
2015-06-30
Grant Code:
Source of funding:
MRC/DFID
Amount:
750000
Role:
Principal Investigator
Start Date:
2019-01-01
End Date:
2021-01-01
Publications
Authors:
Ifedayo Adetifa
, Vaccine. 2018 Nov 8. pii: S0264-410X(18)31504-4.
et al
et al
Date:
2018-11-08
Journal:
Vaccine
Content:
Identifiers:
Authors:
Achoki T
, Lancet Glob Health. 2019 Jan;7(1):e81-e95
Date:
2019-01-07
Journal:
Lancet Global Health
Content:
Identifiers: